Objectives Anti-Ro60 and anti-Ro52 autoantibodies are frequently used as diagnostic biomarkers for Sjogren’s disease, but their clinical significance in systemic lupus erythematosus (SLE) is not well characterised. Methods Patients fulfilling SLE classification criteria were studied according to their anti-Ro status. We defined Ro positivity (Ro+) as those who have either anti-Ro60 or anti-Ro52 positivity. Patient characteristics and disease outcomes, including High Disease Activity Status (HDAS) defined as an ever attainment of SLEDAI2K ≥10, adjusted mean SLEDAI (AMS), and time-adjusted mean clinical SLEDAI (excluding serologic activities) were compared using linear or logistic regressions. Furthermore, isolated or dual positivity of anti-Ro60 and anti-Ro52 were studied. Results Out of 409 patients, 47.2% were Ro+. Ro+ patients were predominantly Asian, had positive dsDNA and hypocomplementemia. They showed a higher likelihood of HDAS (OR 1.65, 95% CI 1.10–2.48, p= 0.015), AMS > 4 (OR 1.84, 1.18–2.88, p= 0.007), and more frequent use of glucocorticoids (OR 1.87, 1.16–3.03, p= 0.011) and immunosuppressants (OR 2.0, 1.26–3.17, p= 0.003). Additionally, 24.4% of Ro+ patients experienced sicca symptoms, and hypergammaglobulinemia was significantly more common. Multivariate analysis confirmed that Asian ethnicity, severe flares, AMS, hypocomplementemia, rheumatoid factor, proteinuria, leucopenia, and sicca symptoms were significantly linked to Ro positivity. Conclusion Anti-Ro positivity is associated with higher disease activity and increased treatment needs. Ro positivity correlates with laboratory abnormalities such as hypocomplementemia and leucopenia. These findings highlight the importance of anti-Ro60/Ro52 testing in the clinical evaluation of SLE.

中文翻译：

---

抗Ro60联合或不联合抗Ro52抗体对系统性红斑狼疮患者的意义


目的 抗 Ro60 和抗 Ro52 自身抗体经常用作干燥病的诊断生物标志物，但它们在系统性红斑狼疮 (SLE) 中的临床意义尚不清楚。方法 根据抗 Ro 状态对符合 SLE 分类标准的患者进行研究。我们将 Ro 阳性 (Ro+) 定义为具有抗 Ro60 或抗 Ro52 阳性的人。使用线性或逻辑回归比较患者特征和疾病结果，包括定义为曾经达到 SLEDAI2K ≥10 的高疾病活动状态 (HDAS)、调整后的平均 SLEDAI (AMS) 和时间调整后的平均临床 SLEDAI（不包括血清学活动） 。此外，还研究了抗Ro60和抗Ro52的分离或双重阳性。结果 409 名患者中，47.2% 为 Ro+。 Ro+ 患者主要是亚洲人，dsDNA 呈阳性且有低补体血症。他们表现出 HDAS 的可能性较高（OR 1.65，95% CI 1.10–2.48，p= 0.015）、AMS > 4（OR 1.84，1.18–2.88，p= 0.007），并且更频繁地使用糖皮质激素（OR 1.87， 1.16–3.03，p= 0.011）和免疫抑制剂（OR 2.0，1.26–3.17，p= 0.003）。此外，24.4% 的 Ro+ 患者出现干燥症状，高丙种球蛋白血症明显更为常见。多变量分析证实，亚洲种族、严重耀斑、AMS、低补体血症、类风湿因子、蛋白尿、白细胞减少和干燥症状与 Ro 阳性显着相关。结论 抗 Ro 阳性与较高的疾病活动度和增加的治疗需求相关。 Ro 阳性与低补体血症和白细胞减少等实验室异常相关。这些发现强调了抗 Ro60/Ro52 检测在 SLE 临床评估中的重要性。